Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26424
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSwisher, Elizabeth M-
dc.contributor.authorKwan, Tanya T-
dc.contributor.authorOza, Amit M-
dc.contributor.authorTinker, Anna V-
dc.contributor.authorRay-Coquard, Isabelle-
dc.contributor.authorOaknin, Ana-
dc.contributor.authorColeman, Robert L-
dc.contributor.authorAghajanian, Carol-
dc.contributor.authorKonecny, Gottfried E-
dc.contributor.authorO'Malley, David M-
dc.contributor.authorLeary, Alexandra-
dc.contributor.authorProvencher, Diane-
dc.contributor.authorWelch, Stephen-
dc.contributor.authorChen, Lee-May-
dc.contributor.authorWahner Hendrickson, Andrea E-
dc.contributor.authorMa, Ling-
dc.contributor.authorGhatage, Prafull-
dc.contributor.authorKristeleit, Rebecca S-
dc.contributor.authorDorigo, Oliver-
dc.contributor.authorMusafer, Ashan-
dc.contributor.authorKaufmann, Scott H-
dc.contributor.authorElvin, Julia A-
dc.contributor.authorLin, Douglas I-
dc.contributor.authorChambers, Setsuko K-
dc.contributor.authorDominy, Erin-
dc.contributor.authorVo, Lan-Thanh-
dc.contributor.authorGoble, Sandra-
dc.contributor.authorMaloney, Lara-
dc.contributor.authorGiordano, Heidi-
dc.contributor.authorHarding, Thomas-
dc.contributor.authorDobrovic, Alexander-
dc.contributor.authorScott, Clare L-
dc.contributor.authorLin, Kevin K-
dc.contributor.authorMcNeish, Iain A-
dc.date2021-05-03-
dc.date.accessioned2021-05-10T07:13:22Z-
dc.date.available2021-05-10T07:13:22Z-
dc.date.issued2021-05-03-
dc.identifier.citationNature Communications 2021; 12(1): 2487en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26424-
dc.description.abstractARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.en
dc.language.isoeng
dc.titleMolecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).en
dc.typeJournal Articleen
dc.identifier.journaltitleNature Communicationsen
dc.identifier.affiliationVall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spainen
dc.identifier.affiliationUniversity of California Los Angeles, Los Angeles, CA, USAen
dc.identifier.affiliationPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canadaen
dc.identifier.affiliationBC Cancer-Vancouver, Vancouver, BC, Canadaen
dc.identifier.affiliationl'Université de Montréal (CHUM), Montréal, QC, Canadaen
dc.identifier.affiliationLawson Health Research Institute, London, ON, Canadaen
dc.identifier.affiliationTom Baker Cancer Center, Calgary, AB, Canadaen
dc.identifier.affiliationGINECO, Centre Léon Bérard and University Claude Bernard, Lyon, Franceen
dc.identifier.affiliationGustave Roussy Cancer Center and INSERM U981, Villejuif, Franceen
dc.identifier.affiliationGuy's and St. Thomas NHS Foundation Trust, London, UKen
dc.identifier.affiliationUniversity of Washington, Seattle, WA, USAen
dc.identifier.affiliationThe University of Texas, MD Anderson Cancer Center, Houston, TX, USAen
dc.identifier.affiliationMemorial Sloan Kettering Cancer Center, New York, NY, USAen
dc.identifier.affiliationRoyal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australiaen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationStanford University Cancer Center and Stanford Cancer Institute, Palo Alto, CA, USAen
dc.identifier.affiliationClovis Oncology, Inc., Boulder, CO, USAen
dc.identifier.affiliationUniversity of Arizona Cancer Center, Tucson, AZ, USAen
dc.identifier.affiliationFoundation Medicine, Inc., Cambridge, MA, USAen
dc.identifier.affiliationMayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationImperial College London, London, UKen
dc.identifier.affiliationRocky Mountain Cancer Centers, Lakewood, CO, USAen
dc.identifier.affiliationUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USAen
dc.identifier.affiliationThe Ohio State University, James Cancer Center, Columbus, OH, USAen
dc.identifier.doi10.1038/s41467-021-22582-6en
dc.type.contentTexten
dc.identifier.orcid0000-0003-2331-0434en
dc.identifier.orcid0000-0002-8109-4023en
dc.identifier.orcid0000-0003-2472-8306en
dc.identifier.orcid0000-0003-1902-3256en
dc.identifier.orcid0000-0002-2371-0844en
dc.identifier.orcid0000-0003-3825-1326en
dc.identifier.orcid0000-0002-1976-5201en
dc.identifier.orcid0000-0002-4900-7145en
dc.identifier.orcid0000-0003-0105-9760en
dc.identifier.orcid0000-0002-3689-5956en
dc.identifier.orcid0000-0002-9387-7586en
dc.identifier.pubmedid33941784
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.